Another available multi-specific killer engager called FLEX-NK, developed by Cytovia Therapeutics in 2021, targets NKp46 and GPC3, a glycoprotein expressed by solid tumors, and CD38 to simultaneously eliminate solid tumors and MM. The gene discussed is NCR1; the disease is Miyoshi myopathy.